From CNBC: 2024-07-25 16:03:38

Shares of Viking Therapeutics soared 28% after announcing plans to fast-track their weight loss injection into a late-stage trial. Analysts predict the weight loss market could reach $150 billion by 2030. Viking is aiming to compete with Novo Nordisk and Eli Lilly. Viking’s injection showed promising results in trials, with positive feedback from the FDA. The drug is expected to launch by 2029, offering a convenient monthly injection option for patients. The drug targets GLP-1 and GIP hormones, leading to significant weight loss in trials, with an oral version in development showing promising results.



Read more at CNBC: Viking Therapeutics stock jumps on weight loss injection trial plans